Lei J, Ingbar DH. Src kinase integrates PI3K/Akt and MAPK/ERK1/2 pathways in T3-induced Na-K-ATPase activity in adult rat alveolar cells. Am
pulmonary edema; 3,5,3=-triiodo-L-thyronine; sodium pump; alveolar fluid clearance THE NA-K-ATPASE, a complex integral membrane protein consisting of ␣-and ␤-subunits, actively transports sodium and potassium across the cell plasma membrane, maintaining the ionic gradients (10, 34) . In addition to preserving electrolyte and fluid balance in cells, organs, and the whole body, Na-KATPase is also a signal transducer and modulator of growth, apoptosis, cell adhesion, and motility (39) . Na-K-ATPase is involved in a broad range of important physiological and pathological conditions, such as alveolar epithelial fluid clearance in the lung. Alveolar fluid clearance is increased by upregulation of active ion transport across the alveolar epithelium that is tightly linked to the Na-K-ATPase activity in alveolar cells (33) . Increasing or restoring the ability of alveolar fluid clearance is critical for patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) (22, 26) .
Thyroid hormones play fundamental roles in the regulation of normal cell functions though genomic and nongenomic mechanisms. In the genomic action, thyroid hormone interacts with its nuclear receptors (TR-␣ and TR-␤) and coregulatory factors (coactivators and corepressors) (5) , thus regulating the transcription of target genes. In the nongenomic action, thyroid hormones rapidly generate biological responses independent of gene transcription (8, 13) , for example by binding to integrin ␣ V ␤ 3 , TR, or other proteins (5, 7) . Most of these nongenomic effects have been described for 3,5,3=-triiodo-L-thyronine (T3) (2), but they also can occur with L-thyroxine (T4) (21) or other related by-products, such as 3,5-diiodo-L-thyronine (27) .
Na-K-ATPase is regulated at many biochemical levels and by a wide variety of agents such as hormones, growth factors, and other molecules. In many cell types, T3 regulates the transcription of Na-K-ATPase via the T3-responsive elements existing in the 5=-flanking region of Na ϩ -K ϩ -ATPase ␣-and ␤-subunits (9) . In contrast, in rat lung alveolar epithelial cells (AECs), we demonstrated that T3 increases the quantity of Na-K-ATPase protein at the plasma membrane and thus enhances Na-K-ATPase activity without altering the gene transcription or total cellular amount of Na-K-ATPase protein (18) , T3 stimulation of Na-K-ATPase required the activation of PI3K via Src kinase (19) , and activation of MAPK/ERK1/2 (20) . However, it is unknown whether activation of Akt, a downstream molecule of PI3K, is also required in the T3-induced Na-K-ATPase activity, and how the PI3K and MAPK/ ERK 1/2 pathways work together to regulate the alveolar Na-K-ATPase activity in AECs. In the present study, we determined that activation of Akt is required for T3-induced activity and increased cell surface expression of alveolar epithelial Na-K-ATPase. We also identified that both PI3K/Akt and MAPK/ERK1/2 pathways required upstream activation of Src kinase in T3-induced Na-K-ATPase activity.
MATERIALS AND METHODS
Materials. T3 and protease inhibitor mixture were purchased from Sigma. PP1 was obtained from Biomol Signal Transduction. Wortmannin, U0126, and biotin-X-N-hydroxysuccinimide ester (watersoluble, cleavable) were purchased from Calbiochem. Polyclonal anti-PKB/Akt, polyclonal anti-phospho-PKB/Akt (Ser473), and polyclonal anti-ERK1/2 and anti-phospho-ERK 1/2 antibodies were obtained from Cell Signaling Technology. Polyclonal anti-Src antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal anti-␣ 1 of Na-K-ATPase antibody was purchased from Upstate Biotechnology (Lake Placid, NY). Cell culture reagents, Waymouth's MB752/1 medium, fetal bovine serum (FBS), and antibiotics were purchased from GIBCO-BRL, Invitrogen. The BCA protein assay kit was purchased from Pierce.
Cell culture. The adult rat ATII-like cell line MP48 (24) was a gift of Dr. G. Hunninghake (University of Iowa). MP48 cells are adenovirus 12S E1A immortalized diploid adult rat type II cells that resemble type II cells in situ. They contain lamellar bodies and express surfactant protein A, cytokeratins and a type II cell-like phospholipid profile for up to 250 days. They also stain with the type II cell specific Maclura pomifera lectin. MP48 cells were maintained in Waymouth's MB752/1 medium with 10% FBS and antibiotics (100 units/ml penicillin, 100 g/ml streptomycin). For the hydrolytic V max activity assay of Na-K-ATPase induced by T3, MP48 cells were grown to ϳ80% confluence in Waymouth's MB752/1 with 10% FBS. Then cells were cultured for 6 h in Waymouth's MB752/1 medium plus stripped 1% FBS in which endogenous T3 and glucocorticoids previously were removed by mixing serum with a resin slurry (5 g of Bio-Rad AG 1-X8 resin/100 ml of serum) as described by Samuels et al. (25) . Removal of endogenous T3 by this method was confirmed by using tracer amounts of radioisotope-labeled T3. For inhibition studies, cells were preincubated with inhibitors for 30 min at 37°C and then were treated with T3 for the indicated term in the continued presence of inhibitors. To detect phosphorylation of Akt or ERK1/2, the cells were starved in medium with 1% of stripped FBS for 24 h before T3 treatment.
Cell transfection. MP48 cells were transfected with FuGENE HD transfection reagent from Roche in six-well plates using 2 g of plasmid DNA per well according to the manufacturer's instructions. Cells were harvested for Na-K-ATPase activity, protein phosphorylation, and biotinylation at 48 h after transfection. For the protein phosphorylation assay, 48 h after transfection, cells were incubated in Waymouth's MB 752/1 medium with 1% stripped FBS overnight and then were used for Western blotting analysis.
Some experiments utilize cells transfected with constitutively active mutants in the absence of T3. The constitutively active p110 subunit in vector pSG5 has been described previously (19) . The constitutively active Src kinase (Src Y527F) in pUSEamp vector was purchased from Upstate Biotechnology. The constitutively active Akt1 in pCS2ϩ vector was a gift of Dr. Anne B. Vojtek in the Department of Biological Chemistry at University of Michigan. This vector (pCS2ϩ⌬PHDDAkt) expresses an activated Akt1, amino acids 131 to 480, in which S473 and T308 were altered to D by PCR mutagenesis (36) . The results of these experiments are termed "basal" conditions because T3 is not present.
Na-K-ATPase activity assay. The hydrolytic activity of Na-KATPase was measured as ouabain-sensitive ATP hydrolysis under Vmax conditions by measuring the release of Pi from ATP as previously described (18) . Na-K-ATPase specific activity was calculated as the difference in free Pi concentration per milligram of protein per minute in the absence and presence of 10 mM ouabain. Results were compared with controls and expressed as the percentage increase or inhibition of control Na-K-ATPase activity.
Src kinase activity assay. The Src kinase activity was detected with a tyrosine kinase assay kit (Colorimetric Detection) purchased from Upstate Cell Signaling Solutions (Millipore). The assay kit is based on phosphorylation of a specific substrate peptide containing tandem repeats of Poly (Glu4-Tyr) using the transfer of the ATP by Src kinase. The phosphorylated substrate was detected by direct ELISA using a monoclonal anti-phosphotyrosine-horseradish peroxidase antibody conjugate. The phosphotransferase activity of Src kinases was measured in immunoprecipitates according to the manufacturer's instructions. The immunoprecipitates for the kinase activity assay were obtained by incubation of 200 g of total cellular protein, 3 g of antibody against Src family kinases, and 20 l of protein A-agarose beads in 1ϫ immunoprecipitation buffer at 4°C for 3 h with gentle rocking. The immunoprecipitates were washed three times with 1ϫ immunoprecipitation buffer and were then washed with Src kinase reaction buffer.
Cell lysis and Western blot. The cells were lysed in lysis buffer containing 20 mM Tris·HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (vol/vol) Triton X-100 with protease inhibitors (1 mM PMSF, 2 g/ml pepstatin, and 10 g/ml each of aprotinin and leupeptin), and inhibitors of phosphatases (2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, and 1 mM Na3VO4). The lysate was drawn 10 times through a 25-gauge needle on ice for further lysis and was then centrifuged at 13,000 rpm for 15 min at 4°C. The supernatant was collected, and the protein concentrations were determined by use of the BCA protein assay kit. Immediately after this step, equal amounts of protein were subjected to Western blotting that was performed as previously described (18) .
Measurement of plasma membrane Na-K-ATPase protein.
To determine the amount of Na-K-ATPase in plasma membrane, the cell surface proteins were biotinylated as previously described (18) . The biotinylated proteins were eluted from the beads by incubation of the biotinylated protein-streptavidin agarose beads for 10 min in 50 l of SDS-containing buffer (5.6% SDS, 240 mM Tris·HCl, pH 7.5, 6% 2-mercaptoethanol, 16% glycerol, and 0.008% bromphenol blue) and analyzed by Western blotting as described above. The densitometric amount of protein was expressed in arbitrary units. To ensure that our biotinylation method was specific for plasma membrane proteins, we probed samples for the presence of biotinylated actin that had been pulled down with avidin beads, but none was detected.
Statistics. All data are expressed as means Ϯ SD of a minimum of three or more independent experiments, unless otherwise noted. In most experiments, individual data points within an experiment represent the mean of at least two replicates. Comparisons involving three or more groups were analyzed by ANOVA and post hoc pairwise comparisons. Differences between means were considered significant at P Ͻ 0.05.
RESULTS

Activation of Akt is required for T3-induced Na-K-ATPase activity and its cell surface expression.
In adult rat AECs, prior work showed that activation of PI3K via Src kinase is required for T3-induced Na-K-ATPase activity and its cell surface expression (19) . However, it is unknown whether activation of Akt (a downstream molecule of PI3K) by T3 is also required for T3-induced Na-K-ATPase activity and cell surface expression of this enzyme. To elucidate this question, we assessed the effects of a specific Akt1/Akt2 inhibitor, Akt inhibitor VIII, on T3-induced Na-K-ATPase activity in MP48 cells. As previously reported, in MP48 cells, T3 maximally increased Na-K-ATPase activity (Fig. 1A) and its cell surface expression (Fig. 1B) at 10 Ϫ5 M concentration and at a 6-h exposure time point. Under this condition, the Akt inhibitor VIII (Ai) completely blocked the T3-induced increase in Na-K-ATPase activity (Fig. 1A) and in the amount of Na-K-ATPase ␣ 1 -subunit protein in the plasma membrane (Fig. 1B) in MP48 cells. As expected, Ai also abolished the T3-induced phosphorylation of Akt (Fig.  1C) . In addition, Ai also blocked the increase in Akt phosphorylation (Fig. 1D) and Na-K-ATPase activity (Fig. 1E) caused by constitutively activated mutants of either Src kinase or PI3K-p110. These data indicated that Akt activation by T3 was required for T3-upregulated Na-K-ATPase function.
To further confirm the stimulatory role of Akt on Na-KATPase, we transiently overexpressed a constitutively activated mutant of Akt1 in MP48 cells. As predicted, overexpression of activated Akt1 significantly increased Na-K-ATPase activity in MP48 cells (Fig. 1E) . The data verified that activated Akt is necessary for T3-stimulation of Na-K-ATPase activity in adult rat AECs and that Akt upregulation is sufficient to increase basal Na-K-ATPase activity.
Effects of inhibitors of Src kinase, PI3K, and MAPK/ERK1/2 on T3 activated phosphorylation of Akt or ERK.
Our prior work showed that T3-induced increases in Na-K-ATPase activity required activation of Src kinase, PI3K, and MAPK/ERK1/2 and that T3 activated PI3K/Akt via activation of Src kinase in MP48 cells (19, 20) . To clarify the relationship among these molecules or pathways in the regulation of Na-K-ATPase activity by T3 in AECs, we assessed the inhibitory effects of specific inhibitors of each signaling transduction pathway on T3-stimulated activation of Src kinase, PI3K/Akt, and MAPK/ ERK1/2. As reported previously, T3 increased Na-K-ATPase activity ( Fig. 2A) , phosphorylation of Akt at Ser473, and phosphorylation of ERK at Thr202/Tyr204 (Fig. 2B) . The Src kinase inhibitor PP1, the PI3K inhibitor wortmannin, and the MEK1/2 inhibitor U0126 each blocked T3-induced Na-KATPase activity (Fig. 2A) . However, U0126 did not block T3-stimulated Akt phosphorylation, and wortmannin did not significantly prevent T3-activated ERK1/2 phosphorylation (Fig. 2B) , indicating that the PI3K/Akt pathway is activated in parallel with MAPK/ERK by T3 in MP48 cells. In contrast, the Src kinase inhibitor (PP1) blocked both Akt phosphorylation and ERK1/2 phosphorylation activated by T3 (Fig. 2B) , indicating that activation of Src was required not only for T3 activation of PI3K/Akt pathway, but also for T3-activated MAPK/ERK1/2 pathway. Furthermore, U0126 was not able to inhibit the T3-induced increase in Src kinase activity (Fig. 2C) , suggesting that MAPK/ERK is downstream of Src kinase. In summary, these data suggested that in MP48 cells the PI3K/ Akt and MAPK/ERK pathways were activated independently by T3, and T3-activated Src kinase was required for the activation of both the PI3K/Akt and MAPK/ERK pathways.
Constitutively active mutant of Src kinase increased basal Na-K-ATPase activity and phosphorylation of both Akt and ERK1/2. To further demonstrate that T3 activates PI3K/Akt and MAPK/ERK1/2 pathways via Src kinase in MP48 cells, we examined the effects of a constitutively active mutant of Src kinase on basal Na-K-ATPase activity, Akt phosphorylation, and ERK1/2 phosphorylation. This active mutant increased significantly basal Na-K-ATPase activity, phosphorylation of Akt at Ser473, and the phosphorylation of ERK1/2 (Fig. 3) , indicating that activation of Src kinase was capable of activating both the PI3K/Akt and MAPK/ERK pathways. These data confirmed that Src kinase coupled PI3K/Akt and MAPK/ ERK1/2 pathways in MP48 cells.
Constitutively active mutants of PI3K did not alter basal phosphorylation of ERK1/2. To confirm that activation of PI3K/Akt occurred in parallel to activation of MAPK/ERK1/2 during upregulation of Na-K-ATPase activity by T3 in AECs, At 48 h after transfection, the cells were incubation with or without Ai (500 nM) overnight. E: constitutively active Akt1 mutant increased basal Na-K-ATPase activity and Ai inhibited the stimulatory effect of active mutants of Src or PI3K on Na-K-ATPase activity. At 48 h after transfection, cells were incubated with or without 0.5 M Ai overnight, and then the Na-K-ATPase activity was measured. V or Vect, vector; M, mutant.
we assessed the effects of a constitutively active mutant of PI3K (p110) on Na-K-ATPase activity, phosphorylation of Akt, and ERK1/2 in MP48 cells. This active mutant, as expected, significantly enhanced basal Na-K-ATPase activity (Fig. 4) and phosphorylation of Akt (Fig. 4C) . However, this active mutant did not significantly change the phosphorylation of ERK1/2 (Fig. 4B ) in MP48 cells. Activation of PI3K also did not alter the basal phosphorylation of MAPK/ERK1/2 in MP48 cells, further verifying that in AECs activation of the PI3K/Akt and MAPK/ERK pathways occurs in parallel.
DISCUSSION
Increasing alveolar fluid clearance is important for recovery from pulmonary edema in patients with ALI/ARDS. Na-KATPase enhances active sodium transport across the alveolar epithelium and thus plays a critical role in lung fluid clearance. In AECs, thyroid hormone T3 rapidly increases the Na-KATPase activity and the amount of Na-K-ATPase protein at cell surface. These effects of T3 require activation of both the Src/PI3K and the MAPK/ERK pathways (19, 20) . To clarify the mechanisms by which T3 increases alveolar Na-K-ATPase activity, we sought to further identify the molecules in these signaling pathways and to define the interactions among these pathways involved in the regulation of Na-K-ATPase function. In the present research, we identified that Akt activation by T3 was required for the T3-induced increases in AEC Na-KATPase activity and plasma membrane protein quantity. Moreover, we demonstrated that the Src family kinase acted upstream of and was a required step (or trigger) for activation of both the PI3K/Akt and MAPK/ERK1/2 pathways, each of which is required for upregulation of AEC Na-K-ATPase activity and cell surface expression. These data deepen the understanding of the molecular mechanisms underlying the regulation of AEC Na-K-ATPase by T3 and identify molecular targets to regulate this response.
Our prior studies demonstrated that both the PI3K and the MAPK/ERK1/2 pathways are required for the increase in Na-K-ATPase activity in AECs. For the former pathway, T3 increases Src kinase and PI3K activities, Akt phosphorylation at Ser473, and Na-K-ATPase activity and cell surface expression. PI3K inhibitors abolished the T3-induced increases in Na-K-ATPase activity and amount of Na-K-ATPase protein at plasma membrane in a nontranscriptional fashion. Overexpression of a constitutively active mutant of PI3K (p110) also increased basal Na-K-ATPase activity and cell surface expression of this enzyme. Thus PI3K is necessary for T3 stimulation of Na-K-ATPase and overexpression of PI3K is sufficient to increase basal Na-K-ATPase activity (19) . However, whether Akt is required for T3 stimulation of Na-K-ATPase activity has not been determined previously. In the present study, a specific inhibitor of Akt, Akt inhibitor VIII, blocked T3-induced increases in both the Na-K-ATPase activity and the amount of this enzyme at cell plasma membrane (Fig. 1) . This inhibitor also blocked the basal increases in Na-K-ATPase activity induced by a constitutively active mutant of either Src kinase or PI3K/p110, indicating that Akt was downstream of these two kinases. Moreover, overexpression of the constitutively active mutant of Akt in MP48 cells increased basal Na-KATPase activity in the absence of T3 (Fig. 1) . These data demonstrated that T3-activated Akt was necessary for T3-induced Na-K-ATPase activity.
Thyroid hormone (T4 and/or T3) is involved in many physiological and pathological processes, typically acting in a genomic fashion. Thyroid hormone also can act by nongenomic mechanisms, stimulating cellular signaling transduction pathways more directly. Many specific examples of nontranscriptional actions of T3 have been defined, such as stimulation of AMP-activated protein kinase (AMPK) activity. Increased hypothalamic AMPK activity leads to increased rat food intake (15) . T3-induced increases in intracellular Ca 2ϩ mobilization and CaMKK␤ activation are responsible for AMPK activation by T3 (40) . T3 also modulates canonical Wnt/␤-catenin signaling, thereby regulating terminal differentiation of growth plate chondrocytes (37, 38) .
In a number of cell types T3 acts independently of transcription to activate either the PI3K/Akt or MAPK/ERK pathways, altering downstream physiological responses.
In multiple other cell types T3 stimulates the PI3K/Akt pathway, sometimes also acting through mammalian target of rapamycin (mTOR) and S6 kinase (S6K). Activation of this pathway is responsible for T3-enhanced neuronal survival (3, 31) , for physiological cardiac growth (16) , and for the expression of ZAKI-4␣, as well as HIF-1␣ and its target genes (GLUT1, PFKP, MCT4) in human fibroblasts (2, 23) . T3 increases NO production in vascular myocytes via activation of the PI3K/Akt pathway, causing NO-dependent rapid relaxation of vascular smooth muscle cells (4) . T3 also protects cardiomyocytes against serum starvation-induced cell death via activation Akt (17) .
Thyroid hormone also acts nontranscriptionally on MAPK pathways, especially affecting ERK1/2. Both T3 and T4 stimulate ERK1/2 in human glioblastoma U-87 MG cells (21) and osteoblast-like cells MG-63 (28) . T3 significantly increases the apoptosis of GH4C1 pituitary cells in serum-depleted conditions by activating ERK (6) . T3 also triggers PKA-and ERK-regulated intracellular pathways that augment hepatocyte survival in the presence of death receptor ligand-induced damage under chronic inflammatory conditions (32) . In contrast, thyroid hormone inhibits ERK phosphorylation in pressure overload-induced hypertrophied mouse hearts through a receptor-mediated mechanism (30) . Thus the impact of thyroid hormone on ERK is cell type specific. Although T3-activated PI3K or MAPK/ERK1/2 are involved in many physiological effects of T3 across a variety of types of cells, the interaction of PI3K and ERK1/2 pathways has not been well defined.
In our present studies, the Src kinase inhibitor, PP1, blocked T3-activation of both the PI3K/Akt and MAPK/ERK 1/2 pathways in AECs. In contrast, the PI3K inhibitor wortmannin had no inhibitory effect on MAPK/ERK activation by T3, and the MAPK/ERK inhibitor U0126 also did not interfere with the activation of either PI3K/Akt (Fig. 2B) or Src kinase by T3 (Fig. 2C) . Moreover, a constitutively active mutant of Src kinase increased phosphorylation levels of both Akt and ERK, Fig. 5 . Proposed mechanism of regulation of Na-K-ATPase by T3 in AECs. T3 activates Src kinase, which then triggers both PI3K/Akt and MAPK/ERK pathways. These 2 pathways initiate the processes that increase the translocation of Na-K-ATPase enzyme from intracellular pool (endosomes) into plasma membrane and its activation, thus enhancing the Na-K-ATPase activity in AECs.
but an active mutant of PI3K (p110) was not able to change the phosphorylation of ERK (Fig. 3) . These data demonstrated that in adult rat AECs the activation of Src family kinases by T3 is required for activation of either the PI3K/Akt or ERK1/2 pathway and that, in turn, each are critical for the stimulation of Na-K-ATPase activity and its cell surface expression.
The interrelationship of thyroid hormone effects on PI3K and ERK have been well studied in one other system: human glioma U-87 MG cells. In these cells, thyroid hormones activate PI3K, Src kinase, and ERK1/2 signaling in a parallel fashion, but acting on at least two distinct binding sites on plasma membrane integrin ␣ V ␤ 3 . One binding site on this integrin binds only T3 and activates the PI3K pathway via Src kinase, stimulating TR-␣ trafficking and HIF-1␣ gene expression. The other binding site on ␣ V ␤ 3 integrin binds both T3 and T4 and activates the MAPK/ERK1/2 pathway, causing translocation of TR-␤ 1 and stimulates ERK1/2-dependent tumor cell proliferation (1, 21) . This result differs from the data obtained in our present studies. It is not surprising that specific cell types in different organs may have different signal transduction responses to thyroid hormones, especially given the cell type-dependent T3-induced upstream signaling mechanisms discussed above. There also are cell type-specific differences in whether thyroid hormones nongenomic actions are mediated through the cell membrane anchored integrin ␣ V ␤ 3 or via the conventional thyroid hormone receptors ␣ and ␤ or a combination. For instance, thyroid hormone (T3 and T4) stimulation of ERK and cell proliferation in human osteoblast-like cells is initiated at integrin ␣ V ␤ 3 (28) . On the other hand, in vascular endothelial cells, T3 increased the association of TR-␣ 1 , but not TR-␤ 1 , with the p85 ␣-subunit of PI3K, leading to the phosphorylation and activation of Akt and endothelial nitric oxide synthase (14) . In neuronal cells, TR-␣ 1 is involved in the activation of PI3K/Akt by T3, and there is enhanced TR␣ 1 -p85␣-Src complex formation (3). In contrast, in the islet ␤-cells T3 activates Akt through the interaction of TR␤ 1 and p85␣ of PI3K (35) . The binding of TR-␤ 1 to the p85␣-subunit of PI3K also accounts for activation of PI3K kinase by T3 in human fibroblasts (2) and in a rat pituitary cell line (GH4C1), whereas TR-␣ does not appears to be involved in this process (29) . In addition, a TR␤ mutant (PV) interacts with the regulatory p85␣ subunit of PI3K to activate the downstream AktmTOR and p70(S6K) and PI3K-integrin-linked kinase-matrix metalloproteinase-2 signaling pathways in thyroid tumors (11, 12) . Thus there is growing evidence that both the initiating events and signal transduction pathways involved in thyroid hormone's nongenomic effects are cell type specific.
Our studies utilized an alveolar type II cell-like cell line, MP48 cells. This cell line is derived from adenovirus 12S E1a immortalization of primary rat type II cells (24) . It exhibits many characteristics of type II cells including staining with Maclura pomifera lectin, presence of lamellar bodies, and expression of SP-A and cytokeratins. Our prior work has demonstrated that MP48 cells and primary rat type II cells have very similar, if not identical, Na-K-ATPase responses to T3. Specifically we previously demonstrated similar increases in Na-K-ATPase activity at two T3 doses and times (18) and that the PI3K inhibitor, wortmannin, inhibits the sodium pump response to T3 (19) . Finally, similarly immortalized fetal AEC lines derived from primary fetal day 18 or 19 AECs, behave identically to their primary cell counterparts in terms of the T3 sodium response. In each aspect of the Na-K-ATPase response to T3 studied to date, MP48 cells have behaved identically to primary rat alveolar type II cells.
The present results add to our prior knowledge of the specific pathways of T3 action in AECs. In AEC, T3 activates Src kinase, which then is required for stimulation of both the PI3K/Akt and MAPK/ERK pathways, thereby increasing the plasma membrane Na-K-ATPase protein quantity and activity (Fig. 5) . In our constitutive mutant overexpression experiments, upregulation of individual kinases in these pathways is sufficient to increase the basal Na-K-ATPase activity in MP48 cells. However, the activation of both pathways is required for T3 stimulation of Na-K-ATPase and therefore is critical for maintaining or upregulating alveolar epithelial Na-K-ATPase activity and alveolar fluid clearance. Impairment of these signaling networks could contribute to the pathogenesis of ALI/ARDS pathogenesis or worsen oxygenation. Understanding the specific mechanistic steps in these pathways may identify molecular targets that permit specific alveolar epithelial interventions, such as Src kinase activation, to stimulate resolution of pulmonary edema in ALI/ARDS patients.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
